This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.

NCT06756451 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematologic Malignancies

Interventions

DRUG: RJK-RT2831 dose-escalation phase Ia
DRUG: RJK-RT2831 Dose Expansion Phase Ib

Sponsor

Nanjing RegeneCore Biotech Co., Ltd.